8:00 am Check-in & Coffee
9:00 – 12:00 Assessing Current & Future Opportunities in Bringing Cell Therapies to the Autoimmune Space
9:00 am Workshop A
Synopsis
Owing to exciting advancements in the applications of cell therapies to autoimmune diseases developers are looking to grasp as many opportunities here as possible. However, with the vast amount of autoimmune indications, numerous cell therapy types, and other available therapy modalities, assessing which indications to tackle and the long-term feasibility of developing a candidate in this space is crucial.
Join this workshop to:
- Learn from experts in the space on how the cell therapy for autoimmune disease landscape has been evolving to grasp novel opportunities and understand areas of unmet need that are feasible to tackleÂ
- Gain insights into key considerations when entering and expanding in this space including raising capital and market trends.Â
- What has the investment in this space been looking like so far and what promise does the future hold?Â
- Evaluate the benefit-to-risk ratio when expanding into new areas and to understand which indications have most unmet need and may benefit most certain cell therapy typesÂ
- What are some new hurdles we haven’t seen in oncology before for developing cell therapy candidates for autoimmune disease in the long run?
12:00pm-1:00pm Lunch Break & Networking
1:00 – 4:00 Outlining Key Considerations for Successful Cell Therapy Trials for Autoimmune Patients
1:00 pm Workshop B
Synopsis
With many developers rapidly moving into clinics with candidates that have demonstrated outstanding preclinical results the community now faces challenges in maximizing clinical outcomes when facing competition for clinical resources with the oncology field and a lack of awareness of cell therapies in the autoimmune space.
Join this workshop to:
- Discuss strategies to unite autoimmune specialists with oncologists to strengthen clinical understanding of cell therapies Â
- Explore successful case studies of patient and physician education of cell therapies to increase overall patient access and availability of physicians for trialsÂ
- Understand key differences between running autologous versus allogeneic trials in the autoimmune spaceÂ
- Troubleshoot pressing challenges in sharing resources in oncology clinics such as apheresis slots, in-patient capacity, budget, and trial priorityÂ
- Compare and contrast trials run in academic centers versus hospital outpatient settings in terms of patient and physician access
